Companhia de Tecidos Norte de Minas Stocks

R$ 0.86Last Updated 15.08.2024

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

R$ 2.71M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
R$ 0.86
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Companhia de Tecidos Norte de Minas produces, markets, exports, imports, and sells yarns and fabrics in Brazil and internationally. It operates through three segments: Wholesale, Retail, and Denim. The company offers bed sheets and pillow cases, sheet sets, tablecloths, towels, rugs, and bath accessories under the CAMEBA name; and clothing apparel, including professional uniforms, accessories, and personal protective equipment for occupational safety. It markets its products under the Santista, Artex, MMartan, and Casas Moysés brand names. As of September 30, 2020, the company operated through a network of 229 stores, including 61 owned and 168 franchised stores, as well as sells products through e-commerce. Companhia de Tecidos Norte de Minas was founded in 1967 and is headquartered in Montes Claros, Brazil.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks